ALL Clinical Trials in Shanghai, Shanghai Municipality
142 recruitingShanghai, Shanghai Municipality, China
Showing 1–20 of 142 trials
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled215 locationsNCT06345729
Recruiting
Phase 1Phase 2
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Small Cell Lung Cancer Extensive Stage
Merck Sharp & Dohme LLC170 enrolled15 locationsNCT07227597
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Stage IV+1 more
Forward Pharmaceuticals Co., Ltd.99 enrolled22 locationsNCT06064812
Recruiting
Phase 3
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.740 enrolled2 locationsNCT07196774
Recruiting
Phase 3
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled2 locationsNCT07111832
Recruiting
Phase 2
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Lung NeoplasmsThoracic NeoplasmsLung Diseases+1 more
Shanghai Pulmonary Hospital, Shanghai, China15 enrolled1 locationNCT06758700
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 3
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
Locally Advanced Breast Cancer
RenJi Hospital316 enrolled1 locationNCT04254263
Recruiting
A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
ctDNAGall Bladder CancerIntrahepatic Cholangiocarcinoma (Icc)+3 more
Yingbin Liu, MD, PhD, FACS1,800 enrolled1 locationNCT07176962
Recruiting
Phase 2
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.66 enrolled1 locationNCT06437509
Recruiting
Phase 1Phase 2
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Non-small Cell Lung Cancer (NSCLC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled1 locationNCT06754930
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Non-small Cell Lung CancerKRAS P.G12C
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205
Recruiting
Phase 2
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.180 enrolled1 locationNCT06439771
Recruiting
Phase 3
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer
Hansoh BioMedical R&D Company460 enrolled9 locationsNCT06498479
Recruiting
Phase 1
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.250 enrolled5 locationsNCT06403735
Recruiting
Phase 1
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma
Shanghai Simnova Biotechnology Co.,Ltd.35 enrolled1 locationNCT06384482
Recruiting
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
Non-small Cell Lung CancerNeuroendocrine CarcinomaHistology Transformation
Fudan University50 enrolled1 locationNCT06369181
Recruiting
Phase 3
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Non-small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.242 enrolled1 locationNCT06080776